

## Instructions to Authors

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

*Tables.* Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

*References.* Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC-IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinassios  
International Institute of Anticancer Research (IIAR)  
Editorial Office of ANTICANCER RESEARCH,  
IN VIVO, CANCER GENOMICS and PROTEOMICS.  
1st km Kapandritiou-Kalamou Road  
P.O. Box 22, GR-19014 Kapandriti, Attiki  
GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.



# 7. International Charité-Mayo- Conference

**Updates in Gynecology:  
A Global Perspective**

17.–20. April 2013  
Berlin

2. ANKÜNDIGUNG · 2ND ANNOUNCEMENT



**Live Surgeries  
Intensive Workshop  
Meet-The-Professor-Session**

**CALL FOR ABSTRACTS**

**[www.charite-mayo.de](http://www.charite-mayo.de)**

*supported by*

**GYNECOLOGIC  
CANCER INTERGROUP**

An Organization of International Cooperative  
Groups for Clinical Trials in Gynecologic Cancers



**Sehr geehrte Kolleginnen und Kollegen,**

wir laden Sie herzlich zur nunmehr 7. Charité-Mayo-Conference nach Berlin ein. Die partnerschaftliche Verbindung der Charité mit der Mayo Clinic hat mittlerweile eine über hundertjährige Tradition. Um neueste Forschungsergebnisse zeitnah in klinische Praxis umsetzen zu können, gilt es, die Daten und Studien nach den Kriterien der Evidence Based Medicine zu analysieren und in den Gesamtkontext zu stellen. Namhafte Experten aus dem In- und Ausland werden zu Diagnostik, Therapie und Nachsorge praxisorientiert Stellung nehmen und eine internationale Diskussion ermöglichen. Über zwölf Stunden Live-OP, ein operativ-anatomischer Workshop und interaktive Tumorkonferenzen erwarten Sie ebenso wie Übersichtsvorträge und Pro- und Contra-Sitzungen zu den heißen Topics der Gynäkologie. Angesichts der großen Zahl neuer zielgerichteter Therapiestrategien führen wir gemeinsam mit dem renommierten EUTROC-Konsortium auch ein translationales Symposium durch. Wir würden uns sehr freuen, Sie vom 17. bis 20. April 2013 persönlich in Berlin begrüßen zu dürfen.

Mit freundlichen Grüßen

Prof. Dr. med. J. Sehouli

Prof. Dr. med. W. Lichtenegger

*Dear colleagues,*

*We warmly invite you to the 7th Charité-Mayo-Conference in Berlin. The cooperative partnership between Charité and Mayo Clinic has a more than centennial tradition by now. To translate newest research results into the clinical day soon, it is necessary to analyse data and trials according to the criteria of evidence based medicine and put them in a global context. Famous experts from home and abroad will present a practice-oriented update in diagnosis, treatment as well as follow-up and allow an international discussion. You can expect more than 12 hours live-surgeries, an operative anatomical workshop and interactive tumorboards as well as overview lectures and pro-con-sessions concerning the hot topics in gynecology. Due to the large number of new targeted therapies, we will also perform a translational symposium in conjunction with the renowned EUTROC consortium. We would be very pleased to greet you personally in Berlin from 17th to 20th April 2013.*

*Sincere regards,*

Prof. Dr. med. J. Sehouli

Prof. Dr. med. W. Lichtenegger

## GEPLANTES PROGRAMM

**MITTWOCH, 17. APRIL 2013 · UROGYNÄKOLOGIE****LIVE-OP**

Moderation: W. Lichtenegger, D-Berlin; F. Ismaeel, D-Berlin  
**Fisteln, Revisions-Operationen (Bänder, Netze), HI-Operationen nach Netzinterposition, unterschiedliche Techniken der Hysterektomie unter Beckenboden-protectiven Aspekten (vaginal, laparoskopisch suprazervikal, total)**  
 K. Baessler, D-Berlin; J. B. Gebhart, USA-Rochester; H. Kölbl, A-Wien; G. Schär, CH-Aarau; K. Tamussino, A-Graz; R. Tunn, D-Berlin

**VORTRÄGE**

**Vaginale Rekonstruktion des Scheidenstumpff prolaps nach Zystektomie**  
 F. Graefe, D-Berlin

**Moderne Behandlung von rezidivierenden Zystitiden**  
 F. Chen, D-Berlin

**Sexuelle Funktionsstörungen nach onkologischen Operationen im kleinen Becken**  
 K. Baessler, D-Berlin

**Roboter-assistierte vs. laparoskopische Chirurgie in der Urogynäkologie**  
 G. Schär, CH-Aarau

**Management intra- und postoperativer Blutungen im Rahmen der Deszensus- und Inkontinenzchirurgie**  
 R. Tunn, D-Berlin

**Definition von Erfolg und Misserfolg in der urogynäkologischen Chirurgie**  
 K. Tamussino, A-Graz

**Gewebersatz in der Urogynäkologie – was ist die beste Strategie?**  
**Die Europäische Perspektive**  
 H. Kölbl, A-Wien  
**Die Amerikanische Perspektive**  
 J. B. Gebhart, USA-Rochester

**INTENSIV-WORKSHOP**

**En-bloc-Resektionsverfahren, Lymphonodektomie und Oberbauchchirurgie beim Ovarialkarzinom**  
 J. Sehouli, D-Berlin; C. Fotopoulou, D-Berlin

**MEET-THE-PROFESSOR-SESSION**

**für Ärzte in der Ausbildung:**  
**Wie man ein guter gynäkologischer Onkologe wird**  
 J. Sehouli, D-Berlin; W. Lichtenegger, D-Berlin;  
 K. Podratz, USA-Rochester

## PLANNED PROGRAMME

**WEDNESDAY, APRIL 17, 2013 · UROGYNECOLOGY****LIVE SURGERY**

Moderation: W. Lichtenegger, D-Berlin; F. Ismaeel, D-Berlin  
**Fistulas; Complications of meshes and tapes; Incontinence procedures after mesh placement, techniques of hysterectomy (vaginal, laparoscopic supracervical, total) with effects/protection of the pelvic floor**  
 K. Baessler, D-Berlin; J. B. Gebhart, USA-Rochester; H. Kölbl, A-Wien; G. Schär, CH-Aarau; K. Tamussino, A-Graz; R. Tunn, D-Berlin

**LECTURES**

**Vaginal reconstruction of vaginal cuff prolapse after cystectomy**  
 F. Graefe, D-Berlin

**Current treatment of recurrent cystitis**  
 F. Chen, D-Berlin

**Sexual dysfunctions after gyn-oncological operations in the pelvis**  
 K. Baessler, D-Berlin

**Robotic vs. Laparoscopic surgery in urogynecology**  
 G. Schär, CH-Aarau

**Management of intra- and postoperative bleedings within prolapse and incontinence surgery**  
 R. Tunn, D-Berlin

**Defining success and failure in urogynecological surgery**  
 K. Tamussino, A-Graz

**Tissue replacement in urogynecology - What is the best strategy?**  
**The European Perspective**  
 H. Kölbl, A-Wien  
**The American Perspective**  
 J. B. Gebhart, USA-Rochester

**INTENSIVE WORKSHOP**

**En-bloc resection techniques, lymph node dissection upper abdomen surgery in ovarian cancer**  
 J. Sehouli, D-Berlin; C. Fotopoulou, D-Berlin

**MEET-THE-PROFESSOR-SESSION**

**for doctors-in-training:**  
**How to become a good gyn-oncologist**  
 J. Sehouli, D-Berlin; W. Lichtenegger, D-Berlin;  
 K. Podratz, USA-Rochester

**DONNERSTAG, 18. APRIL 2013 · MAMMAKARZINOM****LIVE-OP**

Moderation: H. Dieterich, D-Rheinfelden; P. G. Cordeiro, USA-New York

**Plastisch-rekonstruktive Eingriffe**

J.-U. Blohmer, D-Berlin; F. Ismaeel, D-Berlin; M. Rezai, D-Düsseldorf;  
R. Vieira, BR-Rio de Janeiro

**VORTRÄGE****Brustkrebs-Behandlung – gestern, heute, morgen**

U. Veronesi, I-Mailand

**Lymphonodektomie nach Sentinel Node**

V. E. Galimberti, I-Mailand

**Brustrekonstruktion**

Pro Einzeitig: M. Rezai, D-Düsseldorf

Pro Zweizeitig: P. G. Cordeiro, USA-New York

**Aktuelles zur systemischen Therapie des Mammakarzinoms****Möglichkeiten und Grenzen der Gensignaturen**

C. Denkert, D-Berlin

**Aktuelle Entwicklungen der zielgerichteten Therapie in der adjuvanten Situation**

M. Untch, D-Berlin

**Bisphosphonate zur Behandlung des Mammakarzinoms**

S. Kümmel, D-Essen

**Neueste Aspekte der Strahlentherapie**

W. Budach, D-Berlin

**Das primär metastasierte Mammakarzinom****Wann zielgerichtete Therapie?**

C. Jackisch, D-Offenbach

**Wann Chemotherapie?**

V. Möbus, D-Frankfurt

**Interaktives Tumorboard zur adjuvanten und palliativen Therapiesituation**

C. Frei, D-Berlin; R. W. Krättschell, D-Berlin

**FREITAG, 19. APRIL 2013  
ZERVIX-, OVARIAL-, ENDOMETRIUMKARZINOM****LIVE-OP**

Moderation: W. Lichtenegger, D-Berlin; B. Monk, USA-Phoenix

**■ Radikaloperationen beim Ovarialkarzinom (primär/Rezidiv)****■ Deperitonealisierung, En-bloc-Resektionen im Becken und Oberbauch****■ Techniken der pelvinen und paraaortalen Lymphonodektomie**

A. du Bois, D-Essen; C. Fotopoulou, D-Berlin; J. Sehouli, D-Berlin;

I. Vergote, B-Leuven

**VORTRÄGE****Zervixkarzinom****Zervixkarzinom im frühen Stadium: Konisation vs. Trachelektomie**

Pro Konisation: A. Maggioni, I-Mailand

Pro Trachelektomie: C. Köhler, D-Berlin

**Neoadjuvante Chemotherapie beim lokal fortgeschrittenen**

primären Zervixkarzinom

Pro W. Cliby, USA-Rochester

Con B. Monk, USA-Phoenix

**Radikale Hysterektomie beim high risk-Zervixkarzinom (b2/IIb)**

Pro D. Cibula, CZ-Prag

Con S. Marnitz-Schulze, D-Berlin

**Nervenschonende Techniken bei der radikalen Hysterektomie, Übersicht und klinische Relevanz**

S. Fujii, JP-Kyoto

**Ovarialkarzinom****Neoadjuvante Operation des fortgeschrittenen primären Ovarialkarzinoms**

Pro I. Vergote, B-Leuven

Con J. Sehouli, D-Berlin

**THURSDAY, APRIL 18, 2013 · BREAST CANCER****LIVE SURGERY**

Moderation: H. Dieterich, D-Rheinfelden; P. G. Cordeiro, USA-New York

**Plastic and reconstructive operations**

J.-U. Blohmer, D-Berlin; F. Ismaeel, D-Berlin; M. Rezai, D-Düsseldorf;

R. Vieira, BR-Rio de Janeiro

**LECTURES****Breast Cancer Treatment – Yesterday, Today, Tomorrow**

U. Veronesi, I-Mailand

**Lymphadenectomy after sentinel node**

V. E. Galimberti, I-Mailand

**Breast Reconstruction**

Pro One-Stage: M. Rezai, D-Düsseldorf

Pro Two-Stage: P. G. Cordeiro, USA-New York

**Current issues of systemic therapy of breast cancer****Options and limitations of gene signatures**

C. Denkert, D-Berlin

**Current developments of targeted therapy in the adjuvant situation**

M. Untch, D-Berlin

**Bisphosphonates in the treatment of breast cancer**

S. Kümmel, D-Essen

**Current aspects of radiotherapy**

W. Budach, D-Berlin

**The primary metastasized breast cancer****When targeted therapy?**

C. Jackisch, D-Offenbach

**When chemotherapy?**

V. Möbus, D-Frankfurt

**Interactive tumorboard on the adjuvant and palliative therapy situation**

C. Frei, D-Berlin; R. W. Krättschell, D-Berlin

**FRIDAY, APRIL 19, 2013  
CERVICAL, OVARIAN, UTERINE CANCER****LIVE SURGERY**

Moderation: W. Lichtenegger, D-Berlin; B. Monk, USA-Phoenix

**■ Radical surgery in ovarian cancer (primary/relapsed)****■ Deperitonealization, en-bloc-resections in pelvis and upper abdomen****■ Techniques of pelvic and paraaortic lymphadenectomy**

A. du Bois, D-Essen; C. Fotopoulou, D-Berlin; J. Sehouli, D-Berlin;

I. Vergote, B-Leuven

**LECTURES****Cervical cancer****Early stage cervical cancer: Conization vs. Trachelectomy**

Pro Conization: A. Maggioni, I-Mailand

Pro Trachelectomy: C. Köhler, D-Berlin

**Neoadjuvant chemotherapy in locally advanced primary cervical cancer**

Pro W. Cliby, USA-Rochester

Con B. Monk, USA-Phoenix

**Radical hysterectomy in high risk cervical cancer (b2/IIb)**

Pro D. Cibula, CZ-Prague

Con S. Marnitz-Schulze, D-Berlin

**Nerve sparing techniques in radical hysterectomy, overview and clinical relevance**

S. Fujii, JP-Kyoto

**Ovarian cancer****Neoadjuvant surgery for advanced primary ovarian cancer**

Pro I. Vergote, B-Leuven

Con J. Sehouli, D-Berlin

**Sekundäre und tertiäre Zytoreduktion beim Ovarialkarzinomrezidiv**

**Pro** C. Fotopoulou, D-Berlin  
**Con** M. Friedlander, AU-Randwick

**Dosisdichte Chemotherapie beim Ovarialkarzinom**

**Pro** K. Fujiwara, JP-Saitama  
**Con** A. du Bois, E-Essen

**CA125 in der Nachsorge**

**Pro** S. Pignata, I-Neapel  
**Con** C. Marth, A-Innsbruck

**Prognostische Faktoren und klinische Konsequenzen bei der Behandlung des Vulvakarzinoms**

A. van der Zee, NL-Groningen

**Endometriumkarzinom**

**Adjuvante Chemotherapie vs. Radio-Chemotherapie beim fortgeschrittenen Endometriumkarzinom**

**Pro** Chemo: S. Dowdy, USA-Rochester  
**Pro** Radio-Chemo: A. Zeimet, A-Innsbruck

**Lymphknotendissektion beim high risk-Endometriumkarzinom**

**Pro** K. Podratz, USA-Rochester  
**Con** P. Benedetti Panici, I-Rom

**Tumorboard**

W. Cliby, USA-Rochester; H. Gabra, GB-London; T. Herzog, USA-New York;  
 P. Kosian, D-Berlin; S. Pignata, I-Neapel; J. Sehouli, D-Berlin

**SAMSTAG, 20. APRIL 2013 · EUTROC-Symposium**

In Kooperation mit: AGO-Kommission Trafo

**Wirkmechanismen der PARP-Inhibitoren**

J. Ledermann, GB-London

**Antiangiogenese: Pathomechanismen und aktuelle klinische Aspekte**

A. González Martín, E-Madrid

**Folat-rezeptor-gesteuerte Krebstherapie**

R. Chekerov, D-Berlin

**Tyrosinkinase-rezeptoren beim Ovarialkarzinom**

H. Gabra, GB-London

**Aktuelle Studien zum Ovarialkarzinom – Wie ist die Strategie?**

T. Herzog, USA-New York

**Personalisierte Medizin in der klinischen Praxis: Histologische Subtypen und klinische Platin-Resistenz beim Ovarialkarzinom**

J. Green, GB-Liverpool

**Genomisches Profiling des rezidivierenden Ovarialkarzinom**

R. Ganapathi, USA-Charlotte

**Zirkulierende Tumorzellen beim Ovarialkarzinom**

R. Zeillinger, A-Wien

**Uterussarkome: Moderne Prinzipien der Operation und systemischen Behandlung**

C. Tropé, N-Oslo

**Poster-Session**

**Mythen und Fakten über Aszites**

K. Pietzner, D-Berlin

**Borderline-Tumore: Neueste Aspekte der Diagnostik und Behandlung**

S. Mahner, D-Hamburg

**Entstehung und Pathogenese des Ovarialkarzinoms: aktuelle Theorien und Konsequenzen auf Screening, Prävention und Behandlung**

M. Dietel, D-Berlin

**Übersicht der Tumormarker beim Ovarialkarzinom**

I. Braicu, D-Berlin

**Präsentation der drei besten Poster**

Poster Reviewers: I. Braicu, D-Berlin; J. Delinassios, GR-Kapandriti; C. Tropé, N-Oslo

**Secondary and tertiary cytoreduction in relapsed ovarian cancer**

**Pro** C. Fotopoulou, D-Berlin  
**Con** M. Friedlander, AU-Randwick

**Dose dense chemotherapy in ovarian cancer**

**Pro** K. Fujiwara, JP-Saitama  
**Con** A. du Bois, E-Essen

**CA125 in the follow-up**

**Pro** S. Pignata, I-Naples  
**Con** C. Marth, A-Innsbruck

**Prognostic factors and clinical implications on management of vulvar cancer**

A. van der Zee, NL-Groningen

**Endometrial cancer**

**Adjuvant chemotherapy vs. radiochemotherapy for advanced endometrial cancer**

**Pro** Chemo: S. Dowdy, USA-Rochester  
**Pro** Radiochemo: A. Zeimet, A-Innsbruck

**Lymph node dissection for high risk endometrial cancer**

**Pro** K. Podratz, USA-Rochester  
**Con** P. Benedetti Panici, I-Rome

**Tumorboard**

W. Cliby, USA-Rochester; H. Gabra, GB-London; T. Herzog, USA-New York;  
 P. Kosian, D-Berlin; S. Pignata, I-Naples; J. Sehouli, D-Berlin

**SATURDAY, APRIL 20, 2013 · EUTROC-Symposium**

In cooperation with: AGO-Kommission Trafo

**Mechanisms of action of PARP-Inhibitors**

J. Ledermann, GB-London

**Anti-Angiogenesis: understanding the pathways and current clinical aspects**

A. González Martín, E-Madrid

**Folat-receptor guided anticancer therapy**

R. Chekerov, D-Berlin

**Receptor tyrosine kinases in ovarian cancer**

H. Gabra, GB-London

**Current trials in ovarian cancer – the global perspective**

T. Herzog, USA-New York

**Personalized Medicine in Clinical Practice now: Histological Subtypes and Clinical Platinum Resistance in Ovarian Cancer**

J. Green, GB-Liverpool

**Genomic Profiling of Recurrent Ovarian Cancer**

R. Ganapathi, USA-Charlotte

**Circulating Tumor Cells in Ovarian Cancer**

R. Zeillinger, A-Vienna

**Uterine sarcomas: principles of understanding of surgery and systemic treatment**

C. Tropé, N-Oslo

**Poster Session**

**Myths and facts about ascites**

K. Pietzner, D-Berlin

**Borderline tumors: novel aspects of diagnosis and treatment**

S. Mahner, D-Hamburg

**Origin and pathogenesis of ovarian cancer: novel theories and consequences on screening, prevention and treatment**

M. Dietel, D-Berlin

**Overview of tumormarkers in ovarian cancer**

I. Braicu, D-Berlin

**Presentation of the three best Posters**

Poster Reviewers: I. Braicu, D-Berlin;  
 J. Delinassios, GR-Kapandriti; C. Tropé, N-Oslo

## Ort

**Langenbeck-Virchow-Haus**  
Luisenstr. 58/59, 10117 Berlin

## Termin

17.–20. April 2013

## Wissenschaftliche Leitung

Prof. Dr. med. Jalid Sehouli  
Prof. Dr. med. Werner Lichtenegger  
Klinik für Gynäkologie  
European Competence Center for Ovarian Cancer  
Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum  
Augustenburger Platz 1, 13353 Berlin



## Information, Organisation, Veranstalter

Jörg Eickeler · Beratung | Organisation | Veranstaltung  
Neanderstr. 20, 40233 Düsseldorf  
Fon +49 (0)211 30 33 224 | Fax +49 (0)211 30 33 554  
info@eickeler.org

## Organisationskomitee

Prof. Dr. med. Jalid Sehouli, D-Berlin  
Prof. Dr. med. Werner Lichtenegger, D-Berlin  
Priv.-Doz. Dr. med. Christina Fotopoulou, D-Berlin  
Prof. Dr. Karl C. Podratz, USA-Rochester  
Prof. Dr. William A. Cliby, USA-Rochester  
Prof. Dr. Sean C. Dowdy, USA-Rochester

## Homepage

www.charite-mayo.de

## Simultanübersetzung

Simultanübersetzung der Charité-Mayo-Conference  
Englisch-Deutsch/Deutsch-Englisch.

## Venue

**Langenbeck-Virchow-Haus**  
Luisenstr. 58/59, 10117 Berlin / Germany

## Date

April 17–20, 2013

## Scientific Committee

Prof. Dr. med. Jalid Sehouli  
**Prof. Dr. med. Werner Lichtenegger**  
Department of Gynecology  
European Competence Center for Ovarian Cancer  
Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum  
Augustenburger Platz 1, 13353 Berlin / Germany



## Organizer

Jörg Eickeler · Beratung | Organisation | Veranstaltung  
Neanderstr. 20, 40233 Düsseldorf / Germany  
Fon +49 (0)211 30 33 224 | Fax +49 (0)211 30 33 554  
info@eickeler.org

## Organizing Committee

Prof. Dr. med. Jalid Sehouli, D-Berlin  
Prof. Dr. med. Werner Lichtenegger, D-Berlin  
Priv.-Doz. Dr. med. Christina Fotopoulou, D-Berlin  
Prof. Dr. Karl C. Podratz, USA-Rochester  
Prof. Dr. William A. Cliby, USA-Rochester  
Prof. Dr. Sean C. Dowdy, USA-Rochester

## Home Page

www.charite-mayo.de

## Simultaneous Translation

Simultaneous translation of the Charité-Mayo-Conference  
German-English/English-German

## ANMELDUNG

Online-Anmeldung: [www.charite-mayo.de](http://www.charite-mayo.de)  
Anmeldeformular erhältlich unter: [service@eickeler.org](mailto:service@eickeler.org)

## REGISTRATION

Online Registration: [www.charite-mayo.de](http://www.charite-mayo.de)  
Registration Form available at: [service@eickeler.org](mailto:service@eickeler.org)

## CALL FOR ABSTRACTS

### Poster Session zum EUTROC-Symposium

(European Network for Translational Research in Ovarian Cancer)  
Samstag, 20. April 2013

Informationen und Vorgaben: [www.charite-mayo.de](http://www.charite-mayo.de)  
Deadline: 28. Februar 2013

## CALL FOR ABSTRACTS

### Poster session during the EUTROC Symposium

(European Network for Translational Research in Ovarian Cancer)  
Saturday, April 20, 2013

Information and Guidelines: [www.charite-mayo.de](http://www.charite-mayo.de)  
Deadline: February 28, 2013

### Call for Abstracts über laufende Studien

Wir starten einen neuen Aufruf zur Einreichung von Abstracts über laufende Studien. Diese bieten der Forschungsgemeinschaft eine neue Möglichkeit, laufende Studien zu präsentieren, neue klinische Partner zu suchen und neuartige Studiendesigns zu diskutieren. Alle Phasen der klinischen Forschung (Phasen I bis III, unterstützende Behandlung, nicht-pharmakologische Behandlungen) können für die Einreichung eines Abstracts über laufende Studien in Betracht gezogen werden.

#### Benötigte Informationen:

- Wissenschaftlicher Hintergrund der Studie
- Studiendesign, Fallzahlkalkulation
- Geplante Behandlung oder Eingriff
- Einschlusskriterien
- Aktueller Einschluss, ohne Ergebnisse oder Endpunkte zu liefern
  - Einschluss hat schon begonnen
  - Registrierungsnummer der klinischen Studie ist erforderlich

### Call for Trials in Progress Abstracts

We launch a new Call for Trials in Progress Abstracts. They provide a new opportunity for research community to present ongoing trials, look for new clinical partner, and discuss novel trial designs. All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion in a Trials in Progress abstract submission.

#### Information needed for Trial in Progress Section:

- Scientific background for the trial
- Trial design, statistic power
- Planned treatment or intervention
- Inclusion criteria
- Current enrolment, without providing results or endpoints
  - Enrolment has been already started
  - Clinical trial registry number is required



«ETTORE MAJORANA»  
FOUNDATION AND CENTRE  
FOR SCIENTIFIC CULTURE  
INTERNATIONAL SCHOOL  
OF UROLOGY AND NEPHROLOGY



**SIUrO**  
Società Italiana di Urologia Oncologica

## «ETTORE MAJORANA» FOUNDATION AND CENTRE FOR SCIENTIFIC CULTURE

*to pay a permanent tribute to Galileo Galilei, founder of modern science  
and to Enrico Fermi, "the italian navigator", father of the weak forces*

### INTERNATIONAL SCHOOL OF UROLOGY AND NEPHROLOGY

# 14<sup>th</sup> Course: Advances in Urological Oncology “Prostate Cancer: from Molecular and Cellular Biology to Therapeutic Advancement”

The Course will be held under the auspices of: • Italian Society of Urological Oncology (SIUrO) • University of Palermo  
• University of Bologna • Faculty of Medicine of the Catholic University of the Sacred Heart of Rome • Italian Ministry of Health  
• Italian Ministry for Instruction, University and (Scientific) Research • Sicilian Regional Government • World Federation of Scientists

#### PURPOSE OF THE COURSE

The purpose of the Course is to provide state of the art knowledge and future perspectives on basic and translational research, pathology and advanced therapeutic strategies of prostate cancer in a multidisciplinary approach. Scientific sessions will include interactive discussions between the faculty and the participants. International experts in research and clinical management of prostate cancer will share their views and experience with the audience. The Course is the fourth of a series of courses held under the aegis of the Italian Society of Urological Oncology.

#### SCIENTIFIC PRELIMINARY PROGRAMME

Prostate cancer stem cell biology. Epithelial-mesenchymal-transition and evolution of neoplastic cells. Role of microRNAs in cancerogenesis. Functional gene profiling in prostate cancer. Biomarkers. Pitfalls and problems in histopathological evaluation of biopsy. Definition of CRPC and androgen independence. AR pathway in HDPC and CRPC. GnRH-R in prostate cancer: from cell biology to targeted therapeutic strategies. Diagnostic and therapeutic work-up in recurrent disease. First line therapies in CRPC. New AR binding agents. New agents in CRPC. Bone health, skeletal related events and new bone targeting agents. Active surveillance. Prostate Cancer Units.

#### GENERAL INFORMATION

• **Person wishing to attend the Course** should write, **within December 20<sup>th</sup> 2012** to: Prof. Michele Pavone-Macaluso c/o E.DI.PO. s.r.l. Via Libertà, 103 - Palermo - fax +39 091 6251719 - michpav@tin.it - edi.po@tiscali.it, **specifying**: • date and place of birth, together with present nationality • degree and other academic qualifications • present position and place of work, address and e-mail.

• **Accreditation for Continuing Medical Education** (by the Italian Ministry of Health (ECM: *Educazione Continua in Medicina*) will be applied.

• **The registration fee** for participants € 2.200,00 plus VAT, to be paid within February 10<sup>th</sup>, 2013 to the Organising Secretariat – is inclusive of: scientific session, transfer from airport (Palermo or Trapani) to Erice and viceversa, lodging on full board basis and social events.

• **Payment by bank draft (bank fees at your charge)**  
**Bank:** Unicredit, Ag. 7 – Palermo  
IBAN: IT 66 X 02008 04696 000300353901  
Swift Code (BIC): UNCRITM1153  
Beneficiary: E.DI.PO. s.r.l.  
Via Libertà, 103 – 90143 Palermo.

**EMFSC PRESIDENT  
AND DIRECTOR  
OF THE CENTRE**  
Antonino Zichichi

**DIRECTORS  
OF THE COURSE**  
Giario Natale Conti  
Como, Italy  
Gigliola Sica  
Roma, Italy

**DIRECTOR OF THE SCHOOL**  
Michele Pavone-Macaluso

**SCIENTIFIC SECRETARIAT**  
Alessandro Bertaccini – Bologna, Italy  
Enrico Bollito – Orbassano (TO), Italy  
Sergio Bracarda – Arezzo, Italy  
Fortunata Iacopino – Roma, Italy  
Giovanni Luigi Pappagallo – Mirano (VE) – Italy  
Carlo Pavone – Palermo, Italy  
Vittorio Vavassori – Bergamo, Italy  
e-mail: slacavera@libero.it

**ORGANISING SECRETARIAT**  
E.DI.PO. s.r.l. **Serenella La Cavera**  
Via Libertà, 103 - 90143 - Palermo (Italy)  
Tel/Fax. +39.091.6251719  
e-mail: edi.po@tiscali.it slacavera@libero.it

Erice, Sicily - Italy April 16-21, 2013

# in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

## Selection of Recent Articles

Repopulation of the Irradiation Damaged Lung with Bone Marrow-derived Cells. M.E. BERNARD, H. KIM, M.S. RAJAGOPALAN, B. STONE, U. SALIMI, J.-C. RWIGEMA, M.W. EPPERLY, H. SHEN, J.P. GOFF, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, H. WANG, D.B. STOLZ, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

15-Lipoxygenase-1 Induces Lipid Peroxidation and Apoptosis, and Improves Survival in Rat Malignant Glioma. H. VIITA, A. PACHOLSKA, F. AHMAD, J. TIETÄVÄINEN, J. NAARALA, A. HYVÄRINEN, T. WIRTH, S. YLÄ-HERTTUALA (*Kuopio; Joensuu, Finland*)

Identification of Four Isoforms of Aldolase B Down-regulated in Hepatocellular Carcinoma Tissues by Means of Two-dimensional Western Blotting. Y. WANG, Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA, N. IIZUKA, T. TAMESA, I. SAKAIDA, M. OKA, K. NAKAMURA (*Ube, Japan*)

Effects of Polo-like-kinase-1-inhibitor BI 2536 in Squamous Cell Carcinoma Cell lines of the Head and Neck- first In Vitro Results. J. WAGENBLAST, D. HIRTH, L. THRON, C. ARNOLDNER, M. DIENSTHUBER, T. STÖVER, M. HAMBEK (*Frankfurt am Main, Germany; Vienna, Austria*)

Expression Patterns and Potential Action of the Calcium Transport Genes Trpv5, Trpv6, Ncx1 and Pmca1b in the Canine Duodenum, Kidney and Uterus. J.-A. KIM, H. YANG, I. HWANG, E.-M. JUNG, K.-C. CHOI, E.-B. JEUNG (*Chungbuk, Republic of Korea*)

Association of IGF Axis Hormones with Waist-to-Hip Ratio Varies by Physical Activity. K.H. SCHMITZ, D. XIE, V. TEAL, R. BALLARD-BARBASH, D. BERRIGAN (*Philadelphia, PA; Bethesda, MD, USA*)

Post-operative Corticosterone Levels in Plasma and Feces of Mice Subjected to Permanent Catheterization and Automated Blood Sampling. R. SUNDBOM, K.R. JACOBSEN, O. KALLIOKOSKI, J. HAU, K.S.P. ABELSON (*Uppsala, Sweden; Copenhagen, Denmark*)

Familial Hodgkin's Lymphoma in Scandinavia. V. JØNSSON, H. AWAN, E. NYQUIST, M. MAISENHØLDER, T.B. JOHANNESSEN, B. LY, G.E. TJØNNFJORD (*Oslo, Norway*)

Repair of Postauricular Defects Using a New Technique: The Swallowtail Flap. C. MONARCA, M. MARUCCIA, F. PALUMBO, N. SCUDERI (*Rome, Italy*)

Adipocyte-derived Factor as a Modulator of Oxidative Estrogen Metabolism: Implications for Obesity and Estrogen-dependent Breast Cancer. H.L. BRADLOW, D.W. SEPKOVIC, N. TELANG, R. TIWARI (*New York, NY, USA*)

No Cytomegalovirus Detected in the Gastrointestinal Tract of Patients with Active Crohns Disease. M.T. AARNIO, J.P. BÖHM, K.P. NUORVA, R.I. PITKÄNEN, T.H. KUOPIO, M.E. VOUTILAINEN (*Jyväskylä, Finland*)

Colon Cancer Vaccines: An Update (Review). E. MERIKA, M.W. SAIF, A. KATZ, C. SYRIGOS, M. MORSE (*London, UK; Haven, CT; Durham, NC, USA; Athens, Greece*)

Animal Models of N-Methyl-N-Nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials (Review). A. TSUBURA, OY.-C. LAI, H. MIKI, T. SASAKI, N. UEHARA, T. YURI, K. YOSHIZAWA (*Moriguchi, Osaka, Japan*)

Canine Mammary Tumours as a Model to Study Human Breast Cancer: Most Recent Findings (Review). F.L. QUEIROGA, T. RAPOSO, M.I. CARVALHO, J. PRADA, I. PIRES (*Vila Real, Portugal*)

Metastatic Potential of Orthotopic and Heterotopic Models Imaged by GFP and RFP Protein (Review). V. BOBEK, K. KOLOSTOVA, D. PINTEROVA, M. BOUBELIK, R. GURLICH, R.M. HOFFMAN (*Prague, Czech Republic; San Diego, CA, USA*)

Serotonin Transporter Polymorphism in Major Depressive Disorder (MDD), Psychiatric Disorders, and in MDD in Response to Stressful Life Events: Causes and Treatment with Antidepressant (Review). A. DANIELE, R. DIVELLA, A. PARADISO, V. MATTIOLI, F. ROMITO, F. GIOTTA, P. CASAMASSIMA, M. QUARANTA (*Bari, Italy*)

In Vivo Research Using Early Life Stage Models (Review). R. SEABRA, N. BHOGAL (*Nottingham, UK*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

Nuclear Matrix Protein 22 for Bladder Cancer Detection: Comparative Analysis of the BladderChek® and ELISA. G. HATZICHRISTODOULOU, H. KÜBLER, H. SCHWAIBOLD, S. WAGENPFEIL, C. EIBAUER, C. HOFER, J. GSCHWEND, U. TREIBER ( <i>Munich; Reutlingen, Germany</i> ).....	5093
Preoperative Chemoradiotherapy Using Cisplatin plus S-1 Can Induce Downstaging in Patients with Locally Advanced (Stage III) Non-Small-Cell Lung Cancer. M. KATO, H. ONISHI, K. MATSUMOTO, N. TSURUTA, K. HIGUCHI, J. MOTOSHITA, M. KATANO ( <i>Fukuoka, Japan</i> ) .....	5099
Feasibility of <sup>18</sup> F-Fluorodeoxyglucose Positron-emission Tomography for Preoperative Evaluation of Biliary Tract Cancer. I. YAMADA, T. AJIKI, K. UENO, H. SAWA, I. OTSUBO, Y. YOSHIDA, M. SHINZEKI, H. TOYAMA, I. MATSUMOTO, T. FUKUMOTO, A. NAKAO, J. KOTANI, Y. KU ( <i>Kobe; Nishinomiya, Japan</i> ) .....	5105
An Immunoassay Method for the Pharmacokinetics of 5-Fluorouracil in Patients with Gastric Cancer Administered Adjuvant Chemotherapy. H. MATSUMOTO, M. HIGASHIDA, H. KUBOTA, H. MURAKAMI, K. TSUTSUMI, H. NAKASHIMA, Y. OKA, H. OKUMURA, M. NAKAMURA, T. HIRAI ( <i>Kurashiki, Japan</i> ).....	5111
Lysozyme Is Up-regulated in Columnar-lined Barrett's Mucosa: A Possible Natural Defence Mechanism Against Barrett's Esophagus-associated Pathogenic Bacteria. C.A. RUBIO ( <i>Stockholm, Sweden</i> ) .....	5115
Prognostic Factors of Unresectable Pancreatic Cancer Treated with Nafamostat Mesilate Combined with Gemcitabine Chemotherapy. K. FURUKAWA, T. UWAGAWA, R. IWASE, K. HARUKI, Y. FUJIWARA, T. GOCHO, H. SHIBA, T. MISAWA, K. YANAGA ( <i>Tokyo, Japan</i> ) .....	5121
Testicular Sclerosing Sertoli Cell Tumor: An Additional Case and Review of the Literature. E. BRUNOCILLA, C.V. PULTRONE, R. SCHIAVINA, C. ROCCA, G. PASSARETTI, B. CORTI, G. MARTORANA ( <i>Bologna, Italy</i> ) .....	5127
Improved Quality of Life in Patients with Malignant Pleural Effusion Following Videoassisted Thoracoscopic Talc Pleurodesis. Preliminary Results. S.M.M. BASSO, F. MAZZA, B. MARZANO, D.A. SANTEUFEMIA, G.B. CHIARA, F. LUMACHI ( <i>Pordenone; Padova, Italy</i> ) .....	5131
Errata .....	5135
Reviews (pages 4609, 4629, 4639, 4655)	

Borderline Serous Papillary Tumour of the Testis: A Case Report and Review of the Literature. A.S. IBRAHIM, C. LI, M.S. AL-JAFARI ( <i>Toronto, ON, Canada; Warrington, UK</i> ) .....	5011
Along the Pituitary-Testis-Prostate Axis, Serum Total Testosterone Is a Significant Preoperative Variable Independently Contributing to Separating the Prostate Cancer Population into Prostatectomy Gleason Score Groups. A.B. PORCARO, A. PETROZZIELLO, C. GHIMENTON, F. MIGLIORINI, T. SAVA, B. CARUSO, C. COCCO, M. ROMANO, W. ARTIBANI ( <i>Verona, Italy</i> ) .....	5015
Radical Nephrectomy with Transperitoneal Subcostal Incision for Large and Locally Advanced Tumors of the Right Kidney. J. ANASTASIOU, T. KARATZAS, E. FELEKOURAS, T. TOKAS, G. KOUTALELLIS, D. MITROPOULOS, C. CONSTANTINIDES ( <i>Athens, Greece</i> ) .....	5023
<i>c-MYC</i> Amplification in Mucinous Gastric Carcinoma: A Possible Genetic Alteration Leading to Deeply Invasive Tumors. J.-S. CHOI, J. SEO, E.J. JUNG, E.J. KIM, G.K. LEE, W.H. KIM ( <i>Goyang; Anyang; Seoul, South Korea</i> ) .....	5031
Initial Safety and Outcomes of Miriplatin plus Low-dose Epirubicin for Transarterial Chemoembolisation of Hepatocellular Carcinoma. J. IWAZAWA, N. HASHIMOTO, S. OHUE, T. MITANI ( <i>Osaka; Neyagawa, Japan</i> ) .....	5039
Quality of Life and Sexuality of Patients after Treatment for Gynaecological Malignancies: Results of a Prospective Study in 55 Patients. A. PILGER, R. RICHTER, C. FOTOPOULOU, C. BETETA, C. KLAPP, J. SEHOULI ( <i>Berlin, Germany</i> ) .....	5045
Early Relapse Is Associated with High Serum Soluble Interleukin-2 Receptor after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma. T. YAMAUCHI, Y. MATSUDA, M. TAKAI, T. TASAKI, K. TAI, N. HOSONO, E. NEGORO, S. IKEGAYA, K. TAKAGI, S. KISHI, A. YOSHIDA, Y. URASAKI, H. IWASAKI, T. UEDA ( <i>Eiheiji, Fukui, Japan</i> ) .....	5051
Percutaneous Radiofrequency Ablation Therapy for Recurrent Hepatocellular Carcinoma. H. NISHIKAWA, Y. OSAKI, E. IGUCHI, H. TAKEDA, Y. OHARA, A. SAKAMOTO, K. HATAMARU, S. SAITO, A. NASU, R. KITA, T. KIMURA ( <i>Osaka, Japan</i> ) .....	5059
Metronomic Cyclophosphamide with Cisplatin and Bevacizumab: A New Chemotherapeutic Regimen for Refractory Anaplastic Ependymoma. V. LORGIS, O. VARBEDIAN, F. GHIRINGHELLI ( <i>Dijon, France</i> ) .....	5067
Talc Pleurodesis as Surgical Palliation of Patients with Malignant Pleural Effusion. Analysis of Factors Affecting Survival. F. LUMACHI, F. MAZZA, M. ERMANI, G.B. CHIARA, S.M.M. BASSO ( <i>Padova; Pordenone, Italy</i> ) .....	5071
Papillary-serous Adenocarcinoma of the Uterine Cervix during Tamoxifen Therapy after Bilateral Breast Cancer. R. WATROWSKI, E. STRIEPECKE, C. JÄGER, T. BAUKNECHT, C. HORST ( <i>Freiburg, Germany</i> ) .....	5075
Neuroendocrine Carcinoma of the Breast - Diagnostic and Clinical Implications. R. WATROWSKI, C. JÄGER, D. MATTERN, C. HORST ( <i>Freiburg, Germany</i> ) .....	5079
Pelvic Radiotherapy after Renal Transplantation. S. DAHLKE, A. SCHWARZ, F. BRUNS, M. BREMER, M. MIEMIETZ, H. CHRISTIANSEN, A. MEYER ( <i>Hannover, Germany</i> ) .....	5083
Prognostic Value of Preoperative Metabolic Tumor Volumes on PET-CT in Predicting Disease-free Survival of Patients with Stage I Non-small Cell Lung Cancer. Y. LIN, W.-Y. LIN, C.-H. KAO, K.-Y. YEN, S.-W. CHEN, J.-J. YEH ( <i>Taichung; Taipei; Tainan, Taiwan, ROC</i> ) .....	5087

*Clinical Studies*

Primary Bone Lymphomas Thought to Be Osteomyelitis Urgently Demand a Rapid Diagnosis in Bone Pathology. J. MIKA, I. SCHLEICHER, U. GERLACH, C.-P. ADLER, M. UHL, S.M. KNOELLER (Giessen; Freiburg, Germany; Houston, TX, USA) .....	4905
A Study of Serum Biomarkers Associated with Relapse of Cervical Cancer. L.B. MORDHORST, B. SORBE, C. AHLIN (Örebro, Sweden) .....	4913
Clinical Utility of Transarterial Infusion Chemotherapy Using Cisplatin-lipiodol Emulsion for Unresectable Hepatocellular Carcinoma. T. BEPPU, K. SUGIMOTO, K. SHIRAKI, M. TAMEDA, Y. INAGAKI, S. OGURA, C. KASAI, S. KUSAGAWA, K. NOJIRI, M. YONEDA, H. FUKE, N. YAMAMOTO, Y. TAKEI, M. FUJIMORI, T. HASEGAWA, T. YAMANAKA, J. URAKI, M. KASHIMA, H. TAKAKI, A. NAKATSUKA, K. YAMAKADO, K. TAKEDA (Tsu, Mie, Japan) .....	4923
Photodynamic Therapy Using Talaporfin Sodium (Laserphyrin®) for Bile Duct Carcinoma: A Preliminary Clinical Trial. A. NANASHIMA, T. ABO, T. NONAKA, Y. NONAKA, T. MORISAKI, RY. UEHARA, K. OHNITA, D. FUKUDA, G. MURAKAMI, K. TOU, M. KUNIZAKI, S. HIDAKA, T. TSUCHIYA, H. TAKESHITA, K. NAKAO, T. NAGAYASU (Sakamoto, Nagasaki, Japan).....	4931
Medullomyoblastoma: A Case Report and Literature Review of a Rare Tumor Entity. E. SMOLLE, S. AL-QUBATI, H. STEFANITS, C. HABERLER, R. KLEINERT, J. HAYBAECK (Graz; Vienna, Austria; Sada, Yemen) .....	4939
Focus on the Actual Clinical Target Volume Irradiated with Intraoperative Radiotherapy for Breast Cancer. M. GUENZI, A. FOZZA, G. BLANDINO, G. TIMON, L. BELGIOIA, G. VIDANO, F. CAVAGNETTO, M. GUSINU, S. AGOSTINELLI, S. GARELLI, M. ZEVERINO, G. TACCINI, R. CORVÒ (Genoa, Italy) .....	4945
Semi-automated Volumetric Quantification of Tumor Necrosis in Soft Tissue Sarcoma Using Contrast-enhanced MRI. W.L. MONSKY, B. JIN, C. MOLLOY, R.J. CANTER, C.S. LI, T.C. LIN, D. BORYS, W. MACK, I. KIM, M.H. BUONOCORE, A.J. CHAUDHARI (Sacramento; Davis, CA; Seattle, WA, USA) .....	4951
Uncertainty in the Utility of Immunohistochemistry in Mismatch Repair Protein Expression in Epithelial Ovarian Cancer. D. COPPOLA, S.V. NICOSIA, A. DOTY, T.A. SELLERS, J.-H. LEE, J. FULP, Z. THOMPSON, S. GALEB, J. MCLAUGHLIN, S.A. NAROD, J. SCHILDKRAUT, T. PAL (Tampa, FL; Durham, NC, USA; Toronto, ON, Canada) .....	4963
Isolation and Characterization of Bone Marrowderived Progenitor Cells from Malignant Gliomas. K.-T. GUO, K. JUERCHOTT, P. FU, J. SELBIG, S. EIGENBROD, J.-C. TONN, C. SCHICHOR (Munich; Potsdam, Germany) .....	4971
Epistaxis Secondary to Panitumumab in a Patient with Colon Cancer. D.A. KORNREICH, M.W. SAIF (New York, NY, USA).....	4983
Alpha-fetoprotein-producing Carcinoma of the Renal Pelvis Exhibiting Hepatoid and Urothelial Differentiation. H. SAMARATUNGA, D. SAMARATUNGA, N. DUNGLISON, J. PERRY-KEENE, J. NICKLIN, B. DELAHUNT (Brisbane, QLD, Australia; Wellington, New Zealand) .....	4987
Effect of Breast Cancer Adjuvant Therapies on Potential Biomarkers of Pulmonary Inflammation. M. PIPERIS, X. PROVATOPOULOU, A. SAGKRIOTIS, E. KALOGERA, E. AMPATZOGLOU, G.C. ZOGRAFOS, E. ATHANASIOU, A. GOUNARIS (Athens, Greece) .....	4993
Prognostic Significance of ERCC1, RRM1 and BRCA1 in Surgically-treated Patients with Non-small Cell Lung Cancer. M. PESTA, V. KULDA, O. FIALA, J. SAFRANEK, O. TOPOLCAN, G. KRAKOROVA, R. CERNY, M. PESEK (Pilsen, Czech Republic).....	5003

Expression of Human Endogenous Retrovirus-K Coincides with that of Micro-RNA-663 and -638 in Germ-cell Tumor Cells. B. KRAUS, B. MÖNK, K. SLIVA, B.S. SCHNIERLE ( <i>Langen, Germany</i> ) .....	4797
Interaction of <i>MTHFR</i> C677T and A1298C, and <i>MTR</i> A2756G Gene Polymorphisms in Breast Cancer Risk in a Population in Northeast Brazil. R. DE CÁSSIA CARVALHO BARBOSA, D.M. DA COSTA, D.E. CORDEIRO, A.P. VIEIRA, S.H. .RABENHORST ( <i>Fortaleza, CE, Brazil</i> ) .....	4805
Desensitization of NFκB for Overcoming Chemoresistance of Pancreatic Cancer Cells to TNF-α or Paclitaxel. S. FUJIOKA, K. SON, S. ONDA, C. SCHMIDT, G.M. SCRABAS, T. OKAMOTO, T. FUJITA, P.J. CHIAO, K. YANAGA ( <i>Tokyo, Japan; Houston, TX, USA</i> ) .....	4813
Analysis of Type of Cell Death Induced by Topoisomerase Inhibitor SN-38 in Human Oral Squamous Cell Carcinoma Cell Lines. N. TAMURA, K. HIRANO, K. KISNINO, K. HASHIMOTO, O. AMANO, J. SHIMADA, H. SAKAGAMI ( <i>Saitama, Japan</i> ) .....	4823
Suppression of Cell Invasion and Migration by Propofol Are Involved in Down-regulating Matrix Metalloproteinase- 2 and p38 MAPK Signaling in A549 Human Lung Adenocarcinoma Epithelial Cells. K.-C. WU, S.-T. YANG, T.-C. HSIA, J.-S. YANG, S.-M. CHIOU, C.-C. LU, R.S.-C. WU, J.-G. CHUNG ( <i>Kaohsiung; Taichung, Taiwan, ROC</i> ) .....	4833
Studies on Combination of Platinum Drugs Cisplatin and Oxaliplatin with Phytochemicals Anethole and Curcumin in Ovarian Tumour Models. M.U. NESSA, P. BEALE, C. CHAN, J.Q. YU, F. HUQ ( <i>Lidcombe; Concord, NSW, Australia</i> ) .....	4843
Epigallocatechin Gallate Acts Synergistically in Combination with Cisplatin and Designed <i>trans</i> -palladiums in Ovarian Cancer Cells. M.E. MAZUMDER, P. BEALE, C. CHAN, J.Q. YU, F. HUQ ( <i>Lidcombe; Concord, NSW, Australia</i> ) .....	4851
Demethylation of the Region around Exon 2 of <i>MLH1</i> Gene in Gastrointestinal Cancer. Y. TANG, C. LIU, X. WANG, D. LIU, S. INGVARSSON, H. CHEN ( <i>Wuhan, Hubei, China; Keldur, Reykjavik, Iceland</i> ) .....	4861
Dissimilar Immunohistochemical Expression of ERK and AKT between Paired Biopsy and Hepatectomy Tissues of Hepatocellular Carcinoma. Y.-Y. SHAO, C.-L. CHEN, M.-C. HO, C.-C. HUANG, H.-C. TU, CH.-H. HSU, A.-L. CHENG ( <i>Taipei, Taiwan, ROC</i> ) .....	4865
MicroRNA miR-34b/c Enhances Cellular Radiosensitivity of Malignant Pleural Mesothelioma Cells. Y. MAKI, H. ASANO, S. TOYOOKA, J. SOH, T. KUBO, K. KATSUI, T. UENO, K. SHIEN, T. MURAOKA, N. TANAKA, H. YAMAMOTO, K. TSUKUDA, T. KISHIMOTO, S. KANAZAWA, S. MIYOSHI ( <i>Okayama, Japan</i> ).....	4871
Interaction of Radiation and Gefitinib on a Human Lung Cancer Cell Line with Mutant <i>EGFR</i> Gene <i>In Vitro</i> . Y. SATO, T. EBARA, N. SUNAGA, T. TAKAHASHI, T. NAKANO ( <i>Gunma; Saitama, Japan</i> ).....	4877
<i>EVII</i> and <i>MDS1/EVII</i> Expression During Primary Human Hematopoietic Progenitor Cell Differentiation into Various Myeloid Lineages. K. STEINLEITNER, P. RAMPETSREITER, R. KÖFFEL, G. RAMANATHAN, C. MANNHALTER, H. STROBL, R. WIESER ( <i>Vienna, Austria</i> ) .....	4883
Beneficial Oncolytic Effect of Fiber-substituted Conditionally Replicating Adenovirus on Human Lung Cancer. T. KANNO, A. GOTOH, T. NAKANO, M. TAGAWA, T. NISHIZAKI ( <i>Nishinomiya; Chiba, Japan</i> ) .....	4891
Phenotypic Analysis of Monocyte-derived Dendritic Cells Loaded with Tumor Antigen with Heat-shock Cognate Protein-70. S. ITO, Y. NAGATA, S. SUSUMU, A. YONEDA, M. MATSUO, K. YUI, H. UDONO, S. EGUCHI, T. KANEMATSU ( <i>Nagasaki; Okayama, Japan</i> ) .....	4897

Protein Kinase C Regulates Bombesin-induced Rapid VEGF Secretion in Neuroblastoma Cells. C. SCHLEGEL, P. PAUL, S. LEE, K.W. KIM, N. COLON, J. QIAO, D.H. CHUNG ( <i>Nashville, TN, USA</i> ) .....	4691
Antagonistic Effect of Small-molecule Inhibitors of Wnt/ $\beta$ -catenin in Multiple Myeloma. B.A. NARAYANAN, N.A. DOUDICAN, J. PARK, D. XU, N.K. NARAYANAN, R. DASGUPTA, A. MAZUMDER ( <i>New York, NY, USA</i> ) .....	4697
Analysis of <i>p53</i> and miRNA Expression after Irradiation of Glioblastoma Cell Lines. A. SASAKI, Y. UDAKA, Y. TSUNODA, G. YAMAMOTO, M. TSUJI, H. OYAMADA, K. OGUCHI, T. MIZUTANI ( <i>Tokyo; Chiba, Japan</i> ).....	4709
DNA Methylation in ATRA-treated Leukemia Cell Lines Lacking a PML–RAR Chromosome Translocation. R. MIFTAKHOVA, T. SANDBERG, A. HEDBLMOM, T. NEVZOROVA, J.L. PERSSON, A. BREDBERG ( <i>Malmö, Sweden; Kazan, Russia</i> ) .....	4715
Initial Activation Status of the Antioxidant Response Determines Sensitivity to Carboplatin/Paclitaxel Treatment of Ovarian Cancer. D.G. PONS, J. SASTRE-SERRA, M. NADAL-SERRANO, A. OLIVER, M. GARCÍA-BONAFÉ, I. BOVER, P. ROCA, J. OLIVER ( <i>Balearic Islands, Spain</i> ) .....	4723
In NSCLC, VEGF-A Response to Hypoxia May Differ between Squamous Cell and Adenocarcinoma Histology. M.EILERTSEN, I. PETTERSEN, S. ANDERSEN, I. MARTINEZ, T. DONNEM, L.-T. BUSUND, R.M. BREMNES ( <i>Tromso, Norway</i> ) .....	4729
Cytotoxicity and Type of Cell Death Induced by Midazolam in Human Oral Normal and Tumor Cells. S. OHNO, K. KOBAYASHI, S. UCHIDA, O. AMANO, H. SAKAGAMI, H. NAGASAKA ( <i>Saitama, Japan</i> ) .....	4737
Chemokine Receptors and Chemokine Production by CD34 <sup>+</sup> Stem Cell-derived Monocytes in Response to Cancer Cells. M. STEC, J. BARAN, M. BAJ- KRZYWORZEKA, K. WEGLARCZYK, J. GOZDZIK, M. SIEDLAR, M. ZEMBALA ( <i>Kracow, Poland</i> ) .....	4749
An Immobilized Antibody Targeting N-Cadherin Facilitates Spread of N-Cadherin-positive Tumour Cells. D. MAES, M. BRACKE, P. OST ( <i>Ghent, Belgium</i> ).....	4755
Cisplatin Enhances Interaction between p66Shc and HSP27: Its Role in Reorganization of the Actin Cytoskeleton in Renal Proximal Tubule Cells. I. ARANY, J.S. CLARK, D.K. REED, I. EMBER, L.A. JUNCOS ( <i>Jackson, MS, USA; Pecs, Hungary</i> ).....	4759
MTNR1A Receptor Expression in Normal and Pathological Human Salivary Glands. S. ARIAS-SANTIAGO, J. ANEIROS-FERNÁNDEZ, B. ARIAS-SANTIAGO, M.S. GIRÓN-PRIETO, M. CABA-MOLINA, A. LÓPEZ-VALVERDE, J. ANEIROS-CACHAZA, A. CAMPOS, A. CUTANDO ( <i>Granada; Salamanca, Spain</i> ) .....	4765
Non-invasive X-ray Micro-computed Tomographic Evaluation of Indomethacin on Urethane-induced Lung Carcinogenesis in Mice. T. UENO, K. IMAIDA, M. YOSHIMOTO, T. HAYAKAWA, M. TAKAHASHI, T. IMAI, A. YANAKA, K. TSUTA, M. KOMIYA, K. WAKABAYASHI, M. MUTOH ( <i>Tokyo; Noda-shi; Kagawa; Ibaraki; Shizuoka, Japan</i> ) .....	4773
Phenolic Diterpenes Derived from <i>Hyptis incana</i> Induce Apoptosis and G <sub>2</sub> /M Arrest of Neuroblastoma Cells. K. TABATA, M. KIM, M. MAKINO, M. SATOH, Y. SATOH, T. SUZUKI ( <i>Chiba; Tokyo, Japan</i> ) .....	4781
Marked Increase of <i>CYP24A1</i> mRNA Level in Hepatocellular Carcinoma Cell Lines Following Vitamin D Administration. E. HORVATH, P. LAKATOS, B. BALLA, J.P. KÓSA, B. TÓBIÁS, H. JOZILAN, K. BORKA, H.C. HORVÁTH, I. KOVALSZKY, F. SZALAY ( <i>Budapest, Hungary</i> ).....	4791